Your browser doesn't support javascript.
loading
Detailed Phenotyping and Therapeutic Strategies for Intronic ABCA4 Variants in Stargardt Disease.
Khan, Mubeen; Arno, Gavin; Fakin, Ana; Parfitt, David A; Dhooge, Patty P A; Albert, Silvia; Bax, Nathalie M; Duijkers, Lonneke; Niblock, Michael; Hau, Kwan L; Bloch, Edward; Schiff, Elena R; Piccolo, Davide; Hogden, Michael C; Hoyng, Carel B; Webster, Andrew R; Cremers, Frans P M; Cheetham, Michael E; Garanto, Alejandro; Collin, Rob W J.
Affiliation
  • Khan M; Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands; Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Arno G; UCL Institute for Ophthalmology, London, UK; Moorfields Eye Hospital, London, UK; Great Ormond Street Hospital for Children, London, UK.
  • Fakin A; UCL Institute for Ophthalmology, London, UK; Moorfields Eye Hospital, London, UK; Eye Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia.
  • Parfitt DA; UCL Institute for Ophthalmology, London, UK.
  • Dhooge PPA; Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Center, Nijmegen, the Netherlands; Department of Ophthalmology, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Albert S; Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands; Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Bax NM; Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Center, Nijmegen, the Netherlands; Department of Ophthalmology, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Duijkers L; Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Niblock M; UCL Institute for Ophthalmology, London, UK.
  • Hau KL; UCL Institute for Ophthalmology, London, UK.
  • Bloch E; UCL Institute for Ophthalmology, London, UK; Moorfields Eye Hospital, London, UK.
  • Schiff ER; UCL Institute for Ophthalmology, London, UK.
  • Piccolo D; UCL Institute for Ophthalmology, London, UK.
  • Hogden MC; Princess Alexandra Hospital, Brisbane, QLD, Australia.
  • Hoyng CB; Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Center, Nijmegen, the Netherlands; Department of Ophthalmology, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Webster AR; UCL Institute for Ophthalmology, London, UK; Moorfields Eye Hospital, London, UK.
  • Cremers FPM; Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands; Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Cheetham ME; UCL Institute for Ophthalmology, London, UK.
  • Garanto A; Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands; Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Collin RWJ; Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands; Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Center, Nijmegen, the Netherlands. Electronic address: rob.collin@radboudumc.nl.
Mol Ther Nucleic Acids ; 21: 412-427, 2020 Sep 04.
Article in En | MEDLINE | ID: mdl-32653833
ABSTRACT
Stargardt disease is a progressive retinal disorder caused by bi-allelic mutations in the ABCA4 gene that encodes the ATP-binding cassette, subfamily A, member 4 transporter protein. Over the past few years, we and others have identified several pathogenic variants that reside within the introns of ABCA4, including a recurrent variant in intron 36 (c.5196+1137G>A) of which the pathogenicity so far remained controversial. Detailed clinical characterization of this variant confirmed its pathogenic nature, and classified it as an allele of intermediate severity. Moreover, we discovered several additional ABCA4 variants clustering in intron 36. Several of these variants resulted in aberrant splicing of ABCA4, i.e., the inclusion of pseudoexons, while the splicing defects caused by the recurrent c.5196+1137G>A variant strongly increased upon differentiation of patient-derived induced pluripotent stem cells into retina-like cells. Finally, all splicing defects could be rescued by the administration of antisense oligonucleotides that were designed to specifically block the pseudoexon insertion, including rescue in 3D retinal organoids harboring the c.5196+1137G>A variant. Our data illustrate the importance of intronic variants in ABCA4 and expand the therapeutic possibilities for overcoming splicing defects in Stargardt disease.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Mol Ther Nucleic Acids Year: 2020 Document type: Article Affiliation country: Netherlands

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Mol Ther Nucleic Acids Year: 2020 Document type: Article Affiliation country: Netherlands
...